'Momentous Occasion': UCL Experts Greet First Drug Approved for Early Alzheimer's Disease in the UK
August 23, 2024
August 23, 2024
LONDON, England, Aug. 23 (TNSres) -- The University College London issued the following news:
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed the immunotherapy drug, Lecanemab, for use in the early stages of Alzheimer's disease in the UK, following decades of work supported by UCL research.
Lecanemab is the first treatment of Alzheimer's disease licensed for use in Great Britain that shows some evidence of efficacy in slowing progression of t . . .
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed the immunotherapy drug, Lecanemab, for use in the early stages of Alzheimer's disease in the UK, following decades of work supported by UCL research.
Lecanemab is the first treatment of Alzheimer's disease licensed for use in Great Britain that shows some evidence of efficacy in slowing progression of t . . .